The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
Open accessAbstract
vaccine was associated with neutralization titers against the omicron variant that were 20.0 times higher than those assessed after the second dose of vaccine, and these titers may substantially reduce the risk of breakthrough infection.The decline in neutralization of the omicron variant 6 months after the booster injection was similar to the decline in neutralization titers against the D614G variant 7 months after the second dose.The limitations of our study include small sample sets that may not reflect neutralization in diverse populations, differences in the length of time before boosting among the groups, and a lack of post-boost efficacy data.These limitations may be addressed in further studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These inclusion and exclusion criteria were implemented to allow for build-up of immunity after vaccination4,14 and to minimize different types of potential bias, as informed by earlier analyses in the same population.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings support the durability of vaccine protection against COVID-19 hospitalization and death for at least several months after receiving the second dose,13,14,23”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [14]
In the citing paper
“Matching according to these factors was previously shown to provide adequate control of differences in the risk of SARS-CoV-2 exposure in studies of different designs, all of which involved control groups, such as test-negative, case–control studies.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [22]
In the citing paper
“Extensive sensitivity and additional analyses were conducted to investigate effects of potential bias in our earlier studies that used similar methods. These included different adjustments and controls in the analysis and different study inclusion and exclusion criteria to investigate whether effectiveness estimates could have been biased.12,22 These analyses showed consistent findings.2,3,12,17,2”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [22]
In the citing paper
“Although matching was performed according to sex, age, and nationality, matching was not possible for other factors, such as coexisting conditions. However, matching according to these factors provided demonstrable control of bias in our earlier studies.11,12,15,21,22”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [22]
In the citing paper
“These inclusion and exclusion criteria were implemented to minimize different types of potential bias based on earlier analyses in the same population13,14.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [14]
In the citing paper
“However, matching by these factors provided demonstrable control of bias in studies of different epidemiologic designs and that used control groups in Qatar13,14,35–37.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Self-citationChemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01446-y · Cited by 386
Self-citationAbu-Raddad, L. J., Chemaitelly, H. S., Ayoub, H. H., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P. V., Kanaani, Z. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.19623 · Cited by 168
Self-citationHasan, M. R., Kalikiri, M. K. R., Mirza, F., Sundararaju, S., Sharma, A., Xaba, T., Lorenz, S., Chemaitelly, H. S., Kahlout, R. A. E., Tsui, C. K. M., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.006 · Cited by 65
Self-citation
Cited by
Sorted by citations
Items 101–114 of 114
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628929
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628926
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628908
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628914
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628920
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628923
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628911
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628917
Assessing the Impact of the Healthy Vaccinee Effect on COVID-19 Vaccine Effectiveness EstimatesPreprint
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2026) · medRxiv · doi:10.64898/2026.01.02.26343330
Self-citationCOVID-19 Vaccination Strategy and Evidence in Korea
Hwang, Y. H., & Park, W. B. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e114
Cost‐Effectiveness of Vaccination Strategies for COVID‐19: A Systematic Review
Yang, Y., Weng, J., Tao, Y., Luo, B., Lian, D., Li, F., Yan, J., & Chen, Y. (2026) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70136
Healthy vaccinee effect did not bias COVID-19 vaccine effectiveness estimates
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2026) · Communications Health · doi:10.1038/s44528-026-00006-5 · Cited by 1
Self-citationChemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag602
Self-citationSukik, L., Paul, P., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyag210
Self-citation
Metadata
- Authors
- Abu-Raddad, L. J., Chemaitelly, H., & Bertollini, R.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Ministry of Public Health (QA)
- Corresponding author
- Abu-Raddad, Laith J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-03-17
- Volume
- 386
- Issue
- 11
- Pages
- 1091-1093
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8809505
- OpenAlex
- W4210488818
- Cited by
- 114
- References
- 5
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 13 · 2023: 26 · 2022: 51
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Qatar University QSpace (Qatar University) (submittedVersion)
- Funders
- Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine–Qatar
- Qatar Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, Qatar Genome Program, and Qatar University Biomedical Research Center
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, Omicron variant, neutralizing antibodies, waning vaccine effectiveness, breakthrough infection, booster vaccination, D614G mutation, vaccine durability, Qatar
- MeSH terms
- COVID-19, COVID-19 Vaccines, Vaccine Efficacy, 2019-nCoV Vaccine mRNA-1273, Female, Humans, Immunization, Secondary, Male, Qatar, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
